Item 1. Financial Statements.

132K characters. Original on sec.gov · Markdown

Item 1. Financial Statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

(Unaudited)


	September 30, 2021		December 31, 2020

ASSETS
Current Assets:
Cash and cash equivalents	$	145,203	$	383,928
Accounts receivable, net	376,760		331,429
Inventories	258,484		209,873
Other current assets	157,590		137,508
Total current assets	938,037		1,062,738
Long-Term Assets:
Property and equipment, net	573,385		555,167
Operating lease right-of-use assets	106,962		91,171
Goodwill	355,240		243,347
Intangible assets, net	94,976		52,543
Other long-term assets	317,144		289,595
Total long-term assets	1,447,707		1,231,823
TOTAL ASSETS	$	2,385,744	$	2,294,561

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	86,684	$	74,558
Accrued liabilities	431,047		415,648
Current portion of long-term debt	74,990		49,988
Current portion of deferred revenue	41,128		42,567
Total current liabilities	633,849		582,761
Long-Term Liabilities:
Deferred income tax liabilities	15,306		11,707
Long-term debt, net of current portion	778,025		858,492
Long-term deferred revenue, net of current portion	40,391		46,163
Long-term operating lease liabilities	89,720		77,039
Other long-term liabilities	72,993		85,604
Total long-term liabilities	996,435		1,079,005
Total liabilities	1,630,284		1,661,766

Commitments and Contingencies (Note 16)

Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 106,806 shares in 2021 and 106,457 shares in 2020; Outstanding: 84,880 shares in 2021 and 85,449 shares in 2020	10,681		10,646
Additional paid-in capital	1,358,813		1,294,849
Deferred stock units: Outstanding: 90 units in 2021 and 87 units in 2020	5,669		4,503
Retained earnings	2,757,669		2,175,595
Accumulated other comprehensive loss	(52,057)		(53,615)
Treasury stock, at cost: 21,926 shares in 2021 and 21,008 shares in 2020	(3,326,021)		(2,799,890)
Total IDEXX Laboratories, Inc. stockholders’ equity	754,754		632,088
Noncontrolling interest	706		707
Total stockholders’ equity	755,460		632,795
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	2,385,744	$	2,294,561

The accompanying notes are an integral part of these condensed consolidated financial statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(Unaudited)


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020

Revenue:
Product revenue	$	471,787	$	422,283	$	1,406,850	$	1,153,114
Service revenue	338,634		299,506		1,007,420		832,603
Total revenue	810,421		721,789		2,414,270		1,985,717
Cost of Revenue:
Cost of product revenue	166,748		146,804		483,850		396,282
Cost of service revenue	170,752		152,379		497,409		427,897
Total cost of revenue	337,500		299,183		981,259		824,179
Gross profit	472,921		422,606		1,433,011		1,161,538
Expenses:
Sales and marketing	124,434		108,202		358,277		318,526
General and administrative	82,098		105,031		226,194		231,111
Research and development	40,427		37,517		115,703		102,472
Income from operations	225,962		171,856		732,837		509,429
Interest expense	(7,134)		(8,110)		(22,331)		(25,297)
Interest income	122		208		265		417
Income before provision for income taxes	218,950		163,954		710,771		484,549
Provision for income taxes	43,772		17,633		128,698		77,376
Net income	175,178		146,321		582,073		407,173
Less: Net (loss) income attributable to noncontrolling interest	(57)		102		(1)		187
Net income attributable to IDEXX Laboratories, Inc. stockholders	$	175,235	$	146,219	$	582,074	$	406,986

Earnings per Share:
Basic	$	2.06	$	1.71	$	6.82	$	4.77
Diluted	$	2.03	$	1.69	$	6.71	$	4.70
Weighted Average Shares Outstanding:
Basic	85,123		85,314		85,325		85,293
Diluted	86,511		86,690		86,712		86,635

The accompanying notes are an integral part of these condensed consolidated financial statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(Unaudited)


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020

Net income	$	175,178	$	146,321	$	582,073	$	407,173
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(12,967)		7,329		(20,213)		(7,871)
Unrealized gain (loss) on Euro-denominated notes, net of tax expense (benefit) of $498 and $1,335 in 2021 and $(890) and $(1,092) in 2020	1,581		(2,824)		4,235		(3,466)
Unrealized gain (loss) on investments, net of tax expense (benefit) of $0 and $48 in 2021 and $52 and $(129) in 2020	(1)		166		153		(408)
Unrealized gain (loss) on derivative instruments:
Unrealized gain (loss) on foreign currency exchange contracts, net of tax expense (benefit) of $940 and $1,595 in 2021 and $(1,408) and $(161) in 2020	4,109		(6,161)		7,300		(623)
Unrealized gain (loss) on cross currency swaps, net of tax expense (benefit) of $744 and $1,438 in 2021 and $(933) and $(347) in 2020	2,359		(3,941)		4,561		(1,339)
Reclassification adjustment for loss (gain) included in net income, net of tax benefit (expense) of $330 and $1,206 in 2021 and $53 and $(526) in 2020	1,253		538		5,522		(2,036)
Unrealized gain (loss) on derivative instruments	7,721		(9,564)		17,383		(3,998)
Other comprehensive gain (loss), net of tax	(3,666)		(4,893)		1,558		(15,743)
Comprehensive income	171,512		141,428		583,631		391,430
Less: Comprehensive income (loss) attributable to noncontrolling interest	(57)		102		(1)		187
Comprehensive income attributable to IDEXX Laboratories, Inc.	$	171,569	$	141,326	$	583,632	$	391,243

The accompanying notes are an integral part of these condensed consolidated financial statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except per share amounts)

(Unaudited)


	Common Stock
	Number of Shares	$0.10 Par Value		Additional Paid-in Capital		Deferred Stock Units		Retained Earnings		Accumulated Other Comprehensive (Loss) Income		Treasury Stock		Noncontrolling Interest		Total Stockholders’ Equity
Balance December 31, 2020	106,457	$	10,646	$	1,294,849	$	4,503	$	2,175,595	$	(53,615)	$	(2,799,890)	$	707	$	632,795
Net income	—	—		—		—		204,257		—		—		32		204,289
Other comprehensive loss, net	—	—		—		—		—		(5,921)		—		—		(5,921)
Repurchases of common stock, net	—	—		—		—		—		—		(154,033)		—		(154,033)
Common stock issued under stock plans, including excess tax benefit	219	22		17,408		—		—		—		—		—		17,430
Share-based compensation cost	—	—		8,829		46		—		—		—		—		8,875
Balance March 31, 2021	106,676	$	10,668	$	1,321,086	$	4,549	$	2,379,852	$	(59,536)	$	(2,953,923)	$	739	$	703,435
Net income	—	—		—		—		202,582		—		—		24		202,606
Other comprehensive income (loss), net	—	—		—		—		—		11,145		—		—		11,145
Repurchases of common stock	—	—		—		—		—		—		(188,378)		—		(188,378)
Common stock issued under stock plans, including excess tax benefit	72	7		9,771		—		—		—		—		—		9,778
Deferred stock units activity	—	—		(1,035)		1,035		—		—		—		—		—
Share-based compensation cost	—	—		9,591		46		—		—		—		—		9,637
Balance June 30, 2021	106,748	$	10,675	$	1,339,413	$	5,630	$	2,582,434	$	(48,391)	$	(3,142,301)	$	763	$	748,223
Net income	—	—		—		—		175,235		—		—		(57)		175,178
Other comprehensive income (loss), net	—	—		—		—		—		(3,666)		—		—		(3,666)
Repurchases of common stock	—	—		—		—		—		—		(183,720)		—		(183,720)
Common stock issued under stock plans, including excess tax benefit	58	6		9,921		(12)		—		—		—		—		9,915
Share-based compensation cost	—	—		9,479		51		—		—		—		—		9,530
Balance September 30, 2021	106,806	$	10,681	$	1,358,813	$	5,669	$	2,757,669	$	(52,057)	$	(3,326,021)	$	706	$	755,460


	Common Stock
	Number of Shares	$0.10 Par Value		Additional Paid-in Capital		Deferred Stock Units		Retained Earnings		Accumulated Other Comprehensive (Loss) Income		Treasury Stock		Noncontrolling Interest		Total Stockholders’ Equity
Balance December 31, 2019	105,711	$	10,571	$	1,213,517	$	4,462	$	1,595,648	$	(46,182)	$	(2,600,543)	$	352	$	177,825
Cumulative effect of accounting changes	—	—		—		—		(1,829)		—		—		—		(1,829)
Net income	—	—		—		—		111,827		—		—		29		111,856
Other comprehensive loss, net	—	—		—		—		—		(9,064)		—		—		(9,064)
Repurchases of common stock	—	—		—		—		—		—		(187,767)		—		(187,767)
Common stock issued under stock plans, including excess tax benefit	203	20		9,730		—		—		—		—		—		9,750

Share-based compensation cost	—	—		7,238		46		—		—		—		—		7,284
Balance March 31, 2020	105,914	$	10,591	$	1,230,485	$	4,508	$	1,705,646	$	(55,246)	$	(2,788,310)	$	381	$	108,055
Net income	—	—		—		—		148,940		—		—		56		148,996
Other comprehensive loss, net	—	—		—		—		—		(1,786)		—		—		(1,786)
Issuance of common stock	—	—		—		—		—		—		258		—		258
Common stock issued under stock plans, including excess tax benefit	117	12		10,068		—		—		—		—		—		10,080
Deferred stock units activity	—	—		(894)		894		—		—		—		—		—
Share-based compensation cost	—	—		7,797		—		—		—		—		—		7,797
Balance June 30, 2020	106,031	$	10,603	$	1,247,456	$	5,402	$	1,854,586	$	(57,032)	$	(2,788,052)	$	437	$	273,400
Net income (loss)	—	—		—		—		146,219		—		—		102		146,321
Other comprehensive loss, net	—	—		—		—		—		(4,893)		—		—		(4,893)
Repurchases of common stock, net	—	—		—		—		—		—		(360)		—		(360)
Common stock issued under stock plans, including excess tax benefit	251	25		18,706		(12)		—		—		—		—		18,719
Share-based compensation cost	—	—		7,907		21		—		—		—		—		7,928
Balance September 30, 2020	106,282	$	10,628	$	1,274,069	$	5,411	$	2,000,805	$	(61,925)	$	(2,788,412)	$	539	$	441,115

The accompanying notes are an integral part of these condensed consolidated financial statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	For the Nine Months Ended September 30,
	2021		2020

Cash Flows from Operating Activities:
Net income	$	582,073	$	407,173
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	76,901		71,437
Impairment charge	5,148		1,993
Provision for credit losses	1,719		5,235
Deferred income taxes	4,049		(3,363)
Share-based compensation expense	28,042		23,008
Other	2,402		488
Changes in assets and liabilities:
Accounts receivable	(49,050)		(72,409)
Inventories	(46,891)		(25,091)
Other assets and liabilities	(51,961)		30,579
Accounts payable	637		512
Deferred revenue	(7,487)		(10,433)
Net cash provided by operating activities	545,582		429,129
Cash Flows from Investing Activities:
Purchases of property and equipment	(87,761)		(92,768)
Acquisition of intangible assets and equity investments	—		(918)
Acquisitions of a business, net of cash acquired	(161,166)		—
Net cash used by investing activities	(248,927)		(93,686)
Cash Flows from Financing Activities:
Repayments on revolving credit facilities, net	—		(289,625)
Issuance of senior debt	—		200,000
Payment of senior debt	(50,000)		—
Debt issuance costs	—		(4,995)
Payments of acquisition-related contingent considerations and holdbacks	(1,500)		(1,580)
Repurchases of common stock, net	(502,021)		(182,815)
Proceeds from exercises of stock options and employee stock purchase plans	37,428		39,230
Shares withheld for statutory tax withholding payments on restricted stock	(15,501)		(9,029)
Net cash used by financing activities	(531,594)		(248,814)
Net effect of changes in exchange rates on cash	(3,786)		(1,368)
Net (decrease) increase in cash and cash equivalents	(238,725)		85,261
Cash and cash equivalents at beginning of period	383,928		90,326
Cash and cash equivalents at end of period	$	145,203	$	175,587

Supplemental Cash Flow Information:
Cash paid for income taxes	$	96,103	$	79,909
Unpaid property and equipment, reflected in accounts payable and accrued liabilities	$	14,734	$	7,708

The accompanying notes are an integral part of these condensed consolidated financial statements.

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “IDEXX,” the “Company,” “we,” “our,” or “us” refer to IDEXX Laboratories, Inc. and its subsidiaries.

The accompanying unaudited condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2020, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2021, are not necessarily indicative of the results to be expected for the full year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and our Annual Report on Form 10-K for the year ended December 31, 2020, (the “2020 Annual Report”) filed with the SEC.

The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues, and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments, and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenues and expenses.

We have included certain terms and abbreviations used throughout this Quarterly Report on Form 10-Q in the “Glossary of Terms and Selected Abbreviations.”

NOTE 2. ACCOUNTING POLICIES

Significant Accounting Policies

The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2021, are consistent with those discussed in Note 2. Summary of Significant Accounting Policies to the consolidated financial statements in our 2020 Annual Report, except as noted below.

New Accounting Pronouncements Adopted

Effective January 1, 2021, we adopted ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The new guidance is intended to simplify the accounting for income taxes by removing certain exceptions and by updating accounting requirements around goodwill recognized for tax purposes and the allocation of current and deferred tax expense among legal entities, among other minor changes. The adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements.

In July 2021, the FASB issued ASU 2021-05, “Leases (Topic 842); Lessors - Certain Leases with Variable Lease Payments.” ASU 2021-05 requires a lessor to classify a lease with variable payments that do not depend on an index or rate as an operating lease if another lease classification (i.e., sales-type or direct financing) would result in recognition of a day-one loss. We have elected to adopt this standard as of the third quarter of 2021, on a prospective basis. The adoption of ASU 2021-05 did not have an impact on our consolidated financial statements.

New Accounting Pronouncements Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 is intended to provide optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. We do not expect the discontinuation of LIBOR to have a material impact on our consolidated financial statements.

NOTE 3. REVENUE RECOGNITION

Our revenue is recognized when, or as, performance obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to a customer. We exclude sales, use, value-added, and other taxes we collect on behalf of third parties from revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To accurately present the consideration received in exchange for promised products or services, we apply the five-step model outlined below:

1.Identification of a contract or agreement with a customer

2.Identification of our performance obligations in the contract or agreement

3.Determination of the transaction price

4.Allocation of the transaction price to the performance obligations

5.Recognition of revenue when, or as, we satisfy a performance obligation

We enter into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The timing of revenue recognition, billings, and cash collections results in accounts receivable, contract assets and lease receivables as a result of revenue recognized in advance of billings (included within other assets), and contract liabilities or deferred revenue as a result of receiving consideration in advance of revenue recognition within our unaudited condensed consolidated balance sheet. Our payment terms generally range from 30 to 60 days, with exceptions for certain individual customers and geographies. Below is a listing of our major categories of revenue for our products and services:

Diagnostic Products and Accessories. Diagnostic products and accessories revenues, including IDEXX VetLab® consumables and accessories, rapid assay, LPD, Water, and OPTI testing products, are predominantly recognized and invoiced at the time of shipment, which is when the customer obtains control of the product based on legal title transfer and we have the right to payment. We also provide customers with certain consumables that are recognized upon utilization by the customer, which is when we have the right to payment and the risks and rewards of ownership transfer. Shipping costs reimbursed by the customer are included in revenue and cost of sales. As a practical expedient, we do not account for shipping activities as a separate performance obligation.

Reference Laboratory Diagnostic and Consulting Services. Reference laboratory and consulting services revenues are recognized and invoiced when the services are performed.

Instruments, Software and Systems. CAG Diagnostics capital instruments, veterinary software and diagnostic imaging systems revenues are recognized and invoiced when the customer obtains control of the products based on legal title transfer and we have the right to payment, which generally occurs at the time of installation and customer acceptance. Our instruments, software, and systems are often included in one of our significant customer programs, as further described below. For veterinary software systems that include multiple performance obligations, such as perpetual software licenses and computer hardware, we allocate revenue to each performance obligation based on estimates of the price that we would charge the customer for each promised product or service if it were sold on a standalone basis.

Lease Revenue. Revenues from instrument rental agreements and reagent rental programs are recognized either as operating leases on a ratable basis over the term of the agreement or as sales-type leases at the time of installation and customer acceptance. Customers typically pay for the right to use instruments under rental agreements in equal monthly amounts over the term of the rental agreement. Our reagent rental programs provide our customers the right to use our instruments upon entering into agreements to purchase specified amounts of consumables, which are considered embedded leases. For some agreements, the customers are provided with the right to purchase the instrument at the end of the lease term. Lease revenues from these agreements are presented in product revenue on our unaudited condensed consolidated income statement. Lease revenue was approximately $6.3 million and $15.8 million for the three and nine months ended September 30, 2021, respectively, as

compared to $4.5 million and $12.2 million for the three and nine months ended September 30, 2020, respectively, including both operating leases and sales-type leases under ASC 842, Leases, for leases entered into after January 1, 2019, and ASC 840, Leases, for leases entered into prior to 2019. See below for revenue recognition under our reagent rental programs.

Extended Warranties and Post-Contract Support*.* CAG Diagnostics capital instruments and diagnostic imaging systems extended warranties typically provide customers with continued coverage for a period of one to five years beyond the first-year standard warranty. Customers can either pay in full for the extended warranty at the time of instrument or system purchase or can be billed on a quarterly basis over the term of the contract. We recognize revenue associated with extended warranties over time on a ratable basis using a time elapsed measure of performance over the contract term, which approximates the expected timing in which applicable services are performed.

Veterinary software post-contract support provides customers with access to technical support when and as needed through access to call centers and online customer assistance. Post-contract support contracts typically have a term of 12 months and customers are billed for post-contract support in equal quarterly amounts over the term. We recognize revenue for post-contract support services over time on a ratable basis using a time elapsed measure of performance over the contract term, which approximates the expected timing in which applicable services are performed.

On December 31, 2020, our deferred revenue related to extended warranties and post-contract support was $35.1 million, of which approximately $2.8 million and $20.8 million was recognized during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of new agreements, our deferred revenue related to extended warranties and post-contract support was $31.0 million at September 30, 2021. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less and do not adjust for the effect of the financing components when the period between customer payment and revenue recognition is one year or less. Deferred revenue related to extended warranties and post-contract support with an original duration of more than one year was $17.1 million at September 30, 2021, of which approximately 14%, 43%, 25%, 11%, and 7% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. Additionally, we have determined these agreements do not include a significant financing component.

SaaS Subscriptions. We offer a variety of veterinary software and diagnostic imaging SaaS subscriptions including IDEXX Neo®, Animana®, Pet Health Network® Pro, Petly® Plans, Web PACS, rVetLink®, Smart Flow™, Cornerstone®, ezyVet®, and VetRadar®. We recognize revenue for our SaaS subscriptions over time on a ratable basis over the contract term, beginning on the date our service is made available to the customer. Our subscription contracts vary in term from monthly to two years. Customers typically pay for our subscription contracts in equal monthly amounts over the term of the agreement. Deferred revenue related to our SaaS subscriptions is not material.

Contracts with Multiple Performance Obligations. We enter into contracts where customers purchase a combination of IDEXX products and services. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires significant judgment. We determine the transaction price for a contract based on the consideration we expect to receive in exchange for the transferred goods or services. To the extent the transaction price includes variable consideration, such as volume rebates or expected price adjustments, we apply judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. We evaluate constraints based on our historical and projected experience with similar customer contracts.

We allocate revenue to each performance obligation in proportion to the relative standalone selling prices and recognize revenue when transfer of the related goods or services has occurred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. When standalone selling prices for our products or services are not directly observable, we determine the standalone selling prices using relevant information available and apply suitable estimation methods including, but not limited to, the cost plus a margin approach. We recognize revenue as each performance obligation is satisfied, either at a point in time or over time, as described in the revenue categories above. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less.

The following customer programs represent our most significant customer contracts which contain multiple performance obligations:

Customer Commitment Programs. We offer customer incentives upon entering into multi-year agreements to purchase annual minimum amounts of products and services.

Up-Front Customer Loyalty Programs. Our up-front loyalty programs provide customers with incentives in the form of cash payments or IDEXX Points upon entering into multi-year agreements to purchase annual minimum amounts of future products or services. If a customer breaches its agreement, they are required to refund all or a portion of the up-front cash or IDEXX Points, or make other repayments, remedial actions, or both. Up-front incentives to customers in the form of cash or IDEXX Points are not made in exchange for distinct goods or services and are capitalized as customer acquisition costs within other current and long-term assets, which are subsequently recognized as a reduction to revenue over the term of the customer agreement. If these up-front incentives are subsequently utilized to purchase instruments, we allocate total consideration, including future committed purchases less up-front incentives and estimates of expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance. To the extent invoiced instrument revenue exceeds recognized instrument revenue, we record deferred revenue as a contract liability, which is subsequently recognized upon the purchase of future products and services. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition.

On December 31, 2020, our capitalized customer acquisition costs were $148.1 million, of which approximately $10.7 million and $33.3 million was recognized as a reduction of revenue during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of new up-front customer loyalty payments, net of subsequent recognition, our capitalized customer acquisition costs were $157.1 million at September 30, 2021. We monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and nine months ended September 30, 2021, were not material.

Volume Commitment Programs. Our volume commitment programs, such as our IDEXX 360 program, provide customers with a free or discounted instrument or system upon entering into multi-year agreements to purchase annual minimum amounts of products and services. We allocate total consideration, including future committed purchases and expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance in advance of billing the customer, which is also when the customer obtains control of the instrument based on legal title transfer. Our right to future consideration related to instrument revenue is recorded as a contract asset within other current and long-term assets. The contract asset is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition.

On December 31, 2020, our volume commitment contract assets were $115.5 million, of which approximately $6.5 million and $20.1 million was reclassified to accounts receivable when customers were billed for related products and services during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of new placements under volume commitment programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses, our contract assets were $146.1 million at September 30, 2021. We monitor customer purchases over the term of their agreement to assess the realizability of our contract assets and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and nine months ended September 30, 2021, were not material.

For our up-front customer loyalty and volume commitment programs, we estimate future revenues related to multi-year agreements to be approximately $2.7 billion, of which approximately 6%, 25%, 23%, 19%, and 27% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied, for which customers have committed to

purchase goods and services, net of the expected revenue reductions from customer acquisition costs and expected price adjustments, and as a result, are lower than stated contractual commitments by our customers.

Instrument Rebate Programs. Our instrument rebate programs require an instrument purchase and provide customers the opportunity to earn future rebates based on the volume of products and services they purchase over the term of the program. We account for the customer’s right to earn rebates on future purchases as a separate performance obligation and determine the standalone selling price based on an estimate of rebates the customer will earn over the term of the program. Total consideration allocated to identified performance obligations is limited to goods and services that the customer is presently obligated to purchase and does not include estimates of future purchases that are optional. We allocate total consideration to identified performance obligations, including the customer’s right to earn rebates on future purchases, which is deferred and recognized upon the purchase of future products and services, offsetting future rebates as they are earned.

On December 31, 2020, our deferred revenue related to instrument rebate programs was $39.3 million, of which approximately $3.5 million and $11.0 million was recognized when customers purchased eligible products and services and earned rebates during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of new instrument purchases under rebate programs, net of subsequent recognition, our deferred revenue was $33.9 million at September 30, 2021, of which approximately 10%, 34%, 23%, 15%, and 18% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively.

Reagent Rental Programs. Our reagent rental programs provide our customers the right to use our instruments upon entering into multi-year agreements to purchase annual minimum amounts of consumables. These types of agreements include an embedded lease for the right to use our instrument, and we determine the amount of lease revenue allocated to the instrument based on relative standalone selling prices. We evaluate the terms of these embedded leases to determine classification as either a sales-type lease or an operating lease.

Sales-type Reagent Rental Programs. Our reagent rental programs that effectively transfer control of instruments to our customers are classified as sales-type leases, and we recognize instrument revenue and cost in advance of billing the customer, at the time of installation and customer acceptance. Our right to future consideration related to instrument revenue is recorded as a lease receivable within other current and long-term assets, and is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. On December 31, 2020, our lease receivable assets were $11.1 million, of which approximately $0.5 million and $1.6 million was reclassified to accounts receivable when customers were billed for related products and services during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of new placements under sales-type reagent rental programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses, our lease receivable assets were $14.3 million at September 30, 2021. The impacts of discounting and unearned income at September 30, 2021, were not material. Profit and loss recognized at the commencement date and interest income during the three and nine months ended September 30, 2021, were not material. We monitor customer purchases over the term of their agreement to assess the realizability of our lease receivable assets. Impairments during the three and nine months ended September 30, 2021 were not material.

Operating-type Reagent Rental Programs. Our reagent rental programs that do not effectively transfer control of instruments to our customers are classified as operating leases, and we recognize instrument revenue and costs ratably over the term of the agreement. The cost of the instrument is capitalized within property and equipment. During the three and nine months ended September 30, 2021, we transferred instruments of $2.8 million and $8.6 million, respectively, as compared to $2.6 million and $6.6 million for the three and nine months ended September 30, 2020, from inventory to property and equipment. We had impairments of $1.3 million and $5.1 million for the three and nine months ended September 30, 2021, respectively, associated with a write-down of rental assets in certain regions.

We estimate future revenue to be recognized related to our reagent rental programs of approximately $39.1 million, of which approximately 9%, 31%, 25%, 18%, and 17% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied for which customers have committed to future purchases, net of any expected price adjustments, and as a result, may be lower than stated contractual commitments by our customers.

Other Customer Incentive Programs. Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified

purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers and the expected-value method for programs that are offered to a broad group of customers. Revenue adjustments that relate to performance obligations satisfied in prior periods during the three and nine months ended September 30, 2021, were not material. Refund obligations related to customer incentive programs are recorded in accrued liabilities for the actual issuance of incentives, incentives earned but not yet issued and estimates of incentives to be earned in the future.

Program Combinations. At times, we combine elements of our significant customer programs within a single customer contract. We separate each significant program element and include the contract assets, customer acquisition costs, deferred revenues and estimated future revenues within the most relevant program disclosures above. Each customer contract is presented as a net contract asset or net contract liability on our unaudited condensed consolidated balance sheet.

IDEXX Points. IDEXX Points may be applied to trade receivables due to us, converted to cash, or applied against the purchase price of IDEXX products and services. We consider IDEXX Points equivalent to cash. IDEXX Points that have not yet been used by customers are included in accrued liabilities until utilized or expired. Breakage is not material because customers can apply IDEXX Points to trade receivables at any time.

Accounts Receivable. We recognize revenue when it is probable that we will collect substantially all of the consideration to which we will be entitled, based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer. We have no significant customers that accounted for greater than 10% of our consolidated revenues, and we have no concentration of credit risk as of September 30, 2021.

Disaggregated Revenues. We present disaggregated revenue for our CAG segment based on major product and service categories. Our Water segment is comprised of a single major product category. Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment.

The following table presents disaggregated revenue by major product and service categories:


(in thousands)	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
CAG segment revenue:
CAG Diagnostics recurring revenue:	$	638,358	$	567,416	$	1,916,938	$	1,565,595
IDEXX VetLab consumables	252,714		218,605		755,158		603,379
Rapid assay products	76,974		70,593		230,472		192,681
Reference laboratory diagnostic and consulting services	282,301		254,223		851,757		703,300
CAG Diagnostics services and accessories	26,369		23,995		79,551		66,235
CAG Diagnostics capital - instruments	39,401		29,336		105,645		72,040
Veterinary software, services and diagnostic imaging systems	54,736		41,265		148,274		118,478
CAG segment revenue	732,495		638,017		2,170,857		1,756,113

Water segment revenue	38,143		33,272		109,374		95,537
LPD segment revenue	29,126		36,971		101,920		103,369
Other segment revenue	10,657		13,529		32,119		30,698
Total revenue	$	810,421	$	721,789	$	2,414,270	$	1,985,717

Revenue by principal geographic area, based on customers’ domiciles, was as follows:


(in thousands)	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
United States	$	514,343	$	454,836	$	1,502,219	$	1,257,617
Europe, the Middle East and Africa	167,956		147,193		510,759		400,928
Asia Pacific Region	78,239		77,401		246,645		212,663
Canada	32,813		28,710		105,608		78,314
Latin America	17,070		13,649		49,039		36,195
Total revenue	$	810,421	$	721,789	$	2,414,270	$	1,985,717

Costs to Obtain a Contract. We capitalize sales commissions and the related fringe benefits earned by our sales force when considered incremental and recoverable costs of obtaining a contract. Our contracts include performance obligations related to various goods and services, some of which are satisfied at a point in time and others over time. Commission costs related to performance obligations satisfied at a point in time are expensed at the time of sale, which is when revenue is recognized. Commission costs related to long-term service contracts and performance obligations satisfied over time, including extended warranties and SaaS subscriptions, are deferred and recognized on a systematic basis that is consistent with the transfer of the goods or services to which the asset relates. We apply judgment in estimating the amortization period, which ranges from 3 to 7 years, by taking into consideration our customer contract terms, history of renewals, expected length of customer relationship, as well as the useful life of the underlying technology and products. Amortization expense is included in sales and marketing expenses in the accompanying unaudited condensed consolidated statements of income. Deferred commission costs are periodically reviewed for impairment.

On December 31, 2020, our deferred commission costs, included within other assets, were $17.5 million, of which approximately $1.3 million and $4.3 million of commission expense was recognized during the three and nine months ended September 30, 2021, respectively. Furthermore, as a result of commissions related to new extended warranties and SaaS subscriptions, net of subsequent recognition, our deferred commission costs were $19.0 million at September 30, 2021. Impairments of deferred commission costs, during the three and nine months ended September 30, 2021, were not material.

NOTE 4. ACQUISITIONS

We believe that our acquisitions of businesses and other assets enhance our existing businesses by either expanding our geographic range and customer base or expanding our existing product lines. From time to time we may acquire small reference labs or radiology practices that we account for as either asset purchases or business combinations.

During the third quarter of 2021, we acquired the assets of a teleradiology business for approximately $5.4 million, including a contingent payment of $0.3 million. This acquisition expands our current teleradiology capability. The acquired assets primarily consist of a customer relationship intangible of approximately $1.7 million, with a weighted average life of 10 years, and approximately $3.7 million in goodwill. The purchase price allocation is subject to revision as additional information becomes available regarding tax-related matters and contingencies. Goodwill related to this acquisition is expected to be deductible for tax purposes. Pro forma information has not been presented for this acquisition because such information is not material to the financial statements. The results of operations have been included in our CAG segment since the acquisition date. The acquisition expenses were not material.

During the second quarter of 2021, we acquired the assets of the ezyVet cloud-based veterinary software businesses and the shares of ezyVet US, Inc., as well as the VetRadar business assets, for approximately $157.2 million, including an estimated contingent payment of $5 million. The acquired assets include the ezyVet cloud-native practice management system software and the VetRadar cloud-based workflow management software. The acquisition expands our cloud-based software offerings to support our customers with technology solutions that raise the standards of care for patients, improve practice efficiency, and enable more effective communication with pet owners. The fair value of assets acquired were as follows: approximately $32.0 million in customer-related intangible with a weighted average life of 10 years, approximately $8.4 million in technology-related intangibles with a weighted average life of 6 years, approximately $2.4 million in trademarks with a weighted average life of 14 years, approximately $1.8 million in non-compete agreements with a weighted average life of 5 years, approximately $109.4 million in goodwill, representing synergies within our broader CAG portfolio, and approximately $3.2 million in net tangible assets. Goodwill has been allocated based upon the fair value of projected earnings as of the date of the acquisition. The goodwill was allocated as follows: approximately $23.4 million to IDEXX VetLab®, approximately $27.0 million to Reference Laboratory, approximately $11.1 million to Rapid Assay, and approximately $47.9 million to Veterinary Software Services. Goodwill related to this acquisition is expected to be deductible for tax purposes. Pro forma information has not been presented for this acquisition because such information is not material to the financial statements. The results of operations have been included in our CAG segment since the acquisition date. The acquisition expenses were approximately $2.1 million.

During the first quarter of 2021, we acquired the shares of a reference laboratory located in Switzerland for approximately $5.5 million in cash, including holdback and contingent payments of approximately $1.1 million. This acquisition expands our international reference laboratory presence and was accounted for as a business combination. The fair value of the assets acquired consists of approximately $4.3 million in intangible assets, primarily for customer relationships, which will be amortized over 9 years, approximately $1.8 million for goodwill, representing synergies within our broader CAG portfolio, and approximately $0.6 million of liabilities, including deferred taxes associated with the acquired intangible assets. Goodwill related to this acquisition is not deductible for tax purposes. Pro forma information has not been presented for this acquisition because such information is not material to the financial statements. The results of operations have been included in our CAG segment since the acquisition date. The acquisition expenses were not material.

NOTE 5. SHARE-BASED COMPENSATION

The fair value of options, restricted stock units, deferred stock units, and employee stock purchase rights awarded during the three and nine months ended September 30, 2021, totaled $1.8 million and $50.1 million, respectively, as compared to $1.3 million and $39.9 million for the three and nine months ended September 30, 2020, respectively. The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding at September 30, 2021, was $72.6 million, which will be recognized over a weighted average period of approximately 1.6 years. During the three and nine months ended September 30, 2021, we recognized expenses of $9.5 million and $28.0 million, respectively, as compared to $7.9 million and $23.0 million for the three and nine months ended September 30, 2020, respectively, related to share-based compensation.

We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term, or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to or greater than the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:


	For the Nine Months Ended September 30,
	2021			2020

Share price at grant	$	527.49		$	290.15
Share price at exercise	$	531.24		$	290.15
Expected stock price volatility	30		%	27		%
Expected term, in years	6.2			6.0
Risk-free interest rate	0.7		%	1.4		%
Weighted average fair value of options granted	$	169.13		$	84.60

NOTE 6. CREDIT LOSSES

We are exposed to credit losses primarily through our sales of products and services to our customers. We maintain allowances for credit losses for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts receivable by aging category. Historical credit loss experience provides the basis for the estimation of expected credit losses. Adjustments to historical loss information are made for differences in current economic conditions.

Additional allowances may be required if either the financial condition of our customers were to deteriorate, or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. dollar-denominated purchases. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms and due dates. Our activities include timely account reconciliations, dispute resolution and payment confirmations. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We may require collateralized asset support or a prepayment to mitigate credit risk. We do not have any off-balance sheet credit exposure related to our customers.

Accounts Receivable

The allowance for credit losses associated with accounts receivable was $6.5 million and $6.8 million at September 30, 2021 and December 31, 2020, respectively. Accounts receivable reflected on the balance sheet is net of this reserve. Based on an aging analysis, at September 30, 2021, approximately 91% of our accounts receivable had not yet reached the invoice due date and approximately 9% was considered past due, of which substantially all was less than 60 days past due. At December 31, 2020, approximately 88% of our accounts receivable had not yet reached the invoice due date and approximately 12% was considered past due, of which approximately 1.5% was greater than 60 days past due.

Contract assets and lease receivables

The allowance for credit losses associated with the contract assets and lease receivables was $4.3 million and $3.7 million at September 30, 2021 and December 31, 2020, respectively. The assets reflected on the balance sheet are net of these reserves. Historically, we have experienced low credit loss rates on our customer commitment programs and lease receivables. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer.

NOTE 7. INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The components of inventories were as follows:


(in thousands)	September 30, 2021		December 31, 2020

Raw materials	$	59,609	$	45,986
Work-in-process	24,617		20,374
Finished goods	174,258		143,513
Inventories	$	258,484	$	209,873

NOTE 8. LEASES

Maturities of operating lease liabilities were as follows:


(in thousands, except lease term and discount rate)	September 30, 2021

2021 (remainder of year)	$	4,586
2022	24,124
2023	20,195
2024	15,581
2025	12,049
Thereafter	48,987
Total lease payments	125,522
Less imputed interest	(15,364)
Total	$	110,158

Total minimum future lease payments for leases that have not commenced as of September 30, 2021, are immaterial.

Supplemental cash flow information for leases was as follows:


(in thousands)	For the Nine Months Ended September 30, 2021		For the Nine Months Ended September 30, 2020

Cash paid for amounts included in the measurement of operating leases liabilities	$	17,232	$	14,619
Right-of-use assets obtained in exchange for operating lease obligations, net of early lease terminations (a)	$	33,052	$	17,064

(a) Additions for the nine months ended September 30, 2021, include $7.9 million of right-of-use assets obtained with the acquisition of ezyVet.

NOTE 9. OTHER CURRENT AND LONG-TERM ASSETS

Other current assets consisted of the following:


(in thousands)	September 30, 2021		December 31, 2020

Customer acquisition costs	$	48,164	$	43,751
Prepaid expenses	37,462		34,556
Contract assets, net	31,446		23,837
Taxes receivable	16,823		19,476
Deferred sales commissions	6,302		5,738
Other assets	17,393		10,150
Other current assets	$	157,590	$	137,508

Other long-term assets consisted of the following:


(in thousands)	September 30, 2021		December 31, 2020

Customer acquisition costs	$	108,947	$	104,369
Contract assets, net	114,668		91,681
Deferred income taxes	24,861		31,549
Deferred sales commissions	12,695		11,719
Investment in long-term product supply arrangements	9,790		12,065
Taxes receivable	2,450		6,329
Other assets	43,733		31,883
Other long-term assets	$	317,144	$	289,595

NOTE 10. ACCRUED LIABILITIES

Accrued liabilities consisted of the following:


(in thousands)	September 30, 2021		December 31, 2020

Accrued employee compensation and related expenses	161,579		167,649
Accrued expenses	$	124,465	$	112,526
Accrued customer incentives and refund obligations	81,029		75,064
Accrued taxes	43,536		42,676
Current lease liabilities	20,438		17,733
Accrued liabilities	$	431,047	$	415,648

Other long-term liabilities consisted of the following:


(in thousands)	September 30, 2021		December 31, 2020

Accrued taxes	$	58,727	$	60,313
Other accrued long-term expenses	14,266		25,291
Other long-term liabilities	$	72,993	$	85,604

NOTE 11. DEBT

Senior Notes

The following describes all of our currently outstanding unsecured senior notes issued and sold in private placements (collectively, the "Senior Notes") as of September 30, 2021:


(Principal Amount in thousands)

Issue Date	Due Date	Series	Principal Amount		Coupon Rate		Senior Note Agreement

12/11/2013	12/11/2023	2023 Series A Notes	$	75,000	3.94	%	NY Life 2013 Note Agreement
12/11/2013	12/11/2025	2025 Series B Notes	$	75,000	4.04	%	NY Life 2013 Note Agreement
9/4/2014	9/4/2026	2026 Senior Notes	$	75,000	3.72	%	NY Life 2014 Note Agreement
7/21/2014	7/21/2024	2024 Series B Notes	$	75,000	3.76	%	Prudential 2015 Amended Agreement
6/18/2015	6/18/2025	2025 Series C Notes	€	88,857	1.785	%	Prudential 2015 Amended Agreement
2/12/2015	2/12/2022	2022 Series A Notes	$	75,000	3.25	%	MetLife 2014 Note Agreement
2/12/2015	2/12/2027	2027 Series B Notes	$	75,000	3.72	%	MetLife 2014 Note Agreement
3/14/2019	03/14/2029	2029 Series C Notes	$	100,000	4.19	%	MetLife 2014 Note Agreement
4/2/2020	04/02/2030	MetLife 2030 Series D Notes	$	125,000	2.50	%	MetLife 2014 Note Agreement
4/14/2020	04/14/2030	Prudential 2030 Series D Notes	$	75,000	2.50	%	Prudential 2015 Amended Agreement

On July 21, 2021, we paid off our $50.0 million 2021 Series A Notes with cash provided by operations. The aggregate principal amount of our 2022 Series A Notes for $75.0 million will become due and payable on February 12, 2022.

NOTE 12. REPURCHASES OF COMMON STOCK

We primarily acquire shares by repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required statutory withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury stock issued during the three and nine months ended September 30, 2021 and 2020 was not material.

The following is a summary of our open market common stock repurchases, reported on a trade date basis, and shares acquired through employee surrender:


(in thousands, except per share amounts)	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020

Shares repurchased in the open market	274		—		892		721
Shares acquired through employee surrender for statutory tax withholding (1)	1		1		29		31
Total shares repurchased	275		1		921		752

Cost of shares repurchased in the open market	$	183,315	$	—	$	510,937	$	179,623
Cost of shares for employee surrenders	515		360		15,501		9,029
Total cost of shares	$	183,830	$	360	$	526,438	$	188,652

Average cost per share - open market repurchases	$	668.33	$	—	$	572.10	$	249.20
Average cost per share - employee surrenders	$	688.35	$	393.12	$	547.90	$	292.03
Average cost per share - total	$	668.38	$	393.12	$	571.36	$	250.96

(1) For the quarters ended September 30, 2021 and 2020, the number of shares acquired though employee surrender for statutory tax withholding were below rounding thresholds.

NOTE 13. INCOME TAXES

Our effective income tax rate was 20.0% for the three months ended September 30, 2021, as compared to 10.8% for the three months ended September 30, 2020, and 18.1% for the nine months ended September 30, 2021, as compared to 16.0% for the nine months ended September 30, 2020. The increase in our effective tax rate for the three months ended September 30, 2021, as compared to the same period in the prior year, was primarily driven by a decrease in the tax benefits from share-based compensation and the resolution of uncertain tax positions. The increase in our effective tax rate for the nine months ended September 30, 2021, as compared to the same period in the prior year, was primarily driven by a decrease in the tax benefits from share-based compensation and the resolution of uncertain tax positions.

The effective tax rate for the three and nine months ended September 30, 2021, differed from the U.S. statutory tax rate of 21% primarily due to tax benefits from share-based compensation.

NOTE 14. ACCUMULATED OTHER COMPREHENSIVE INCOME

The changes in AOCI, net of tax, consisted of the following:


	For the Nine Months Ended September 30, 2021
			Unrealized Gain (Loss) on Cash Flow Hedges, Net of Tax		Unrealized (Loss) Gain on Net Investment Hedges, Net of Tax
(in thousands)	Unrealized Gain (Loss) on Investments, Net of Tax		Foreign Currency Exchange Contracts		Euro-Denominated Notes		Cross Currency Swaps		Cumulative Translation Adjustment		Total

Balance as of December 31, 2020	$	(272)	$	(9,934)	$	(5,982)	$	(2,159)	$	(35,268)	$	(53,615)
Other comprehensive income (loss) before reclassifications	153		7,300		4,235		4,561		(20,213)		(3,964)
Loss reclassified from accumulated other comprehensive income	—		5,522		—		—		—		5,522
Balance as of September 30, 2021	$	(119)	$	2,888	$	(1,747)	$	2,402	$	(55,481)	$	(52,057)


	For the Nine Months Ended September 30, 2020
			Unrealized Gain (Loss) on Cash Flow Hedges, Net of Tax		Unrealized Gain (Loss) on Net Investment Hedges, Net of Tax
(in thousands)	Unrealized (Loss) Gain on Investments, Net of Tax		Foreign Currency Exchange Contracts		Euro-Denominated Notes		Cross Currency Swaps		Cumulative Translation Adjustment		Total

Balance as of December 31, 2019	$	110	$	(736)	$	1,396	$	3,467	$	(50,419)	$	(46,182)
Other comprehensive (loss) income before reclassifications	(408)		(623)		(3,466)		(1,339)		(7,871)		(13,707)
Gain reclassified from accumulated other comprehensive income	—		(2,036)		—		—		—		(2,036)
Balance as of September 30, 2020	$	(298)	$	(3,395)	$	(2,070)	$	2,128	$	(58,290)	$	(61,925)

The following tables present components and amounts reclassified out of AOCI to net income:


(in thousands)	Affected Line Item in the Statements of Income	Amounts Reclassified from AOCI For the Three Months Ended September 30,
		2021		2020
Gain (loss) on derivative instruments classified as cash flow hedges included in net income:
Foreign currency exchange contracts	Cost of revenue	$	(1,583)	$	(591)
	Tax expense (benefit)	(330)		(53)
	Gain (loss), net of tax	$	(1,253)	$	(538)


(in thousands)	Affected Line Item in the Statements of Income	Amounts Reclassified from AOCI For the Nine Months Ended September 30,
		2021		2020
Gain (loss) on derivative instruments classified as cash flow hedges included in net income:
Foreign currency exchange contracts	Cost of revenue	$	(6,728)	$	2,562
	Tax expense (benefit)	(1,206)		526
	Gain (loss), net of tax	$	(5,522)	$	2,036

NOTE 15. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options and the total unrecognized compensation expense for unvested share-based compensation awards, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed, and issuance is not contingent. See Note 5 to the consolidated financial statements in our 2020 Annual Report for additional information regarding deferred stock units.

The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share:


(in thousands)	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2021	2020	2021	2020

Shares outstanding for basic earnings per share	85,123	85,314	85,325	85,293

Shares outstanding for diluted earnings per share:
Shares outstanding for basic earnings per share	85,123	85,314	85,325	85,293
Dilutive effect of share-based payment awards	1,388	1,376	1,387	1,342
	86,511	86,690	86,712	86,635

Certain awards and options to acquire shares have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive awards and options:


(in thousands)	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2021	2020	2021	2020

Weighted average number of shares underlying anti-dilutive awards	—	1	0	—
Weighted average number of shares underlying anti-dilutive options	129	10	114	236

NOTE 16. COMMITMENTS, CONTINGENCIES AND GUARANTEES

Commitments

See “Note 8. Leases”, for more information regarding our lease commitments.

Contingencies and Guarantees

We are subject to claims that may arise in the ordinary course of business, including with respect to actual and threatened litigation and other matters. We accrue for loss contingencies when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. However, the results of legal actions cannot be predicted with certainty, and therefore our actual losses with respect to these contingencies could be higher and lower than our accruals. Except for the litigation matter described below, at September 30, 2021, our accruals with respect to actual and threatened litigation were not material.

We are a defendant in an ongoing litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement. The plaintiff has asserted a claim of approximately $50 million, inclusive of interest through June 30, 2020, alleging that the incorrect royalty provision was applied to certain licensed products and services throughout the agreement term and that royalties were also due on non-licensed diagnostic services that were provided concurrently with licensed services. The trial court previously ruled in favor of the plaintiff in this matter and we are appealing the judgment and continue to vigorously defend ourselves against the plaintiff’s allegations. While we believe the claim is without merit, litigation is inherently unpredictable and there can be no assurance that we will prevail in this matter. During the third quarter of 2020, we established an accrual of $27.5 million related to this ongoing matter, which represents the amount of a possible loss that we have determined to be probable and estimable. We have not made any adjustments to this accrual since it was established. The actual cost of resolving this matter may be higher or lower than the amount we have accrued.

From time to time, we have received notices alleging that our products infringe third party proprietary rights, although we are not aware of any pending litigation with respect to such claims. Patent litigation frequently is complex and expensive, and the outcome of patent litigation can be difficult to predict. There can be no assurance that we will prevail in any infringement proceedings that may be commenced against us. If we lose any such litigation, we may be stopped from selling certain products and/or we may be required to pay damages as a result of the litigation.

We have had no significant changes to our contingencies and guarantees discussed in Note 16 to the consolidated financial statements in our 2020 Annual Report.

NOTE 17. SEGMENT REPORTING

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve producer efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment. Our Other operating segment combines and presents products and services for the human medical diagnostics (“OPTI Medical”) market with our out-licensing arrangements. Assets are not allocated to segments for internal reporting purposes.

The following is a summary of segment performance:



(in thousands)	For the Three Months Ended September 30,
	CAG		Water		LPD		Other		Consolidated Total
2021
Revenue	$	732,495	$	38,143	$	29,126	$	10,657	$	810,421

Income from operations	$	201,947	$	17,599	$	3,600	$	2,816	$	225,962
Interest expense, net									(7,012)
Income before provision for income taxes									218,950
Provision for income taxes									43,772
Net income									175,178
Less: Net loss attributable to noncontrolling interest									(57)
Net income attributable to IDEXX Laboratories, Inc. stockholders									$	175,235

2020
Revenue	$	638,017	$	33,272	$	36,971	$	13,529	$	721,789

Income from operations	$	139,434	$	15,243	$	10,505	$	6,674	$	171,856
Interest expense, net									(7,902)
Income before provision for income taxes									163,954
Provision for income taxes									17,633
Net income									146,321
Less: Net income attributable to noncontrolling interest									102
Net income attributable to IDEXX Laboratories, Inc. stockholders									$	146,219


(in thousands)	For the Nine Months Ended September 30,
	CAG		Water		LPD		Other		Consolidated Total
2021
Revenue	$	2,170,857	$	109,374	$	101,920	$	32,119	$	2,414,270

Income from operations	$	649,892	$	49,599	$	24,276	$	9,070	$	732,837
Interest expense, net									(22,066)
Income before provision for income taxes									710,771
Provision for income taxes									128,698
Net income									582,073
Less: Net loss attributable to noncontrolling interest									(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders									$	582,074

2020
Revenue	$	1,756,113	$	95,537	$	103,369	$	30,698	$	1,985,717

Income from operations	$	426,062	$	43,383	$	28,417	$	11,567	$	509,429
Interest expense, net									(24,880)
Income before provision for income taxes									484,549
Provision for income taxes									77,376
Net income									407,173
Less: Net income attributable to noncontrolling interest									187
Net income attributable to IDEXX Laboratories, Inc. stockholders									$	406,986

See “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the three and nine months ended September 30, 2021 and 2020.

NOTE 18. FAIR VALUE MEASUREMENTS

U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non-recurring basis and certain financial assets and liabilities that are not measured at fair value in our unaudited condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows:


Level 1						Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date.
Level 2						Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3						Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers in or out of Level 3 of the fair value hierarchy during the three and nine months ended September 30, 2021.

Our cross currency swap contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our cross currency swap contracts classified as derivative instruments using prevailing market conditions as of the close of business on each balance sheet date. The product of this calculation is then adjusted for counterparty risk.

Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.

The amounts outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit”) and senior notes (“long-term debt”) are measured at carrying value in our unaudited condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using Level 2 inputs. The estimated fair value of our Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $928.2 million and $853.6 million, respectively, as of September 30, 2021, and $1.0 billion and $909.1 million, respectively, as of December 31, 2020.

The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy:


(in thousands)
As of September 30, 2021	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Balance at September 30, 2021

Assets
Money market funds (1)	$	76	$	—	$	—	$	76
Equity mutual funds (2)	$	913	$	—	$	—	$	913
Cross currency swaps (3)	$	—	$	3,158	$	—	$	3,158
Foreign currency exchange contracts (3)	$	—	$	5,075	$	—	$	5,075
Liabilities

Foreign currency exchange contracts (3)	$	—	$	1,698	$	—	$	1,698
Deferred compensation (4)	$	913	$	—	$	—	$	913
Contingent payments - acquisitions	$	—	$	—	$	5,230	$	5,230


(in thousands)
As of December 31, 2020	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Balance at December 31, 2020

Assets
Money market funds (1)	$	76	$	—	$	—	$	76
Equity mutual funds (2)	$	1,145	$	—	$	—	$	1,145
Foreign currency exchange contracts (3)	$	—	$	125	$	—	$	125
Liabilities
Cross currency swaps (3)	$	—	$	2,841	$	—	$	2,841
Foreign currency exchange contracts (3)	$	—	$	12,373	$	—	$	12,373
Deferred compensation (4)	$	1,145	$	—	$	—	$	1,145

(1)Money market funds with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of September 30, 2021 and December 31, 2020, consisted of demand deposits.

(2)Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability.

(3)Cross currency swaps and foreign currency exchange contracts are included within other current assets, other long-term assets, accrued liabilities, or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.

(4)A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Contingent Consideration

We have classified our liability for contingent consideration related to acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which includes the achievements of future revenues. The contingent consideration is included within other short-term liabilities.

We record changes in the estimated fair value of contingent consideration in the condensed consolidated statements of income. Changes in contingent consideration liabilities are measured at fair value on a recurring basis using unobservable inputs (Level 3) and during the nine months ended September 30, 2021, are as follows:


(in thousands)	Fair Value

Contingent consideration as of December 31, 2020	$	—
Contingent consideration recorded from acquisitions (Note 4)	5,230
Change in estimated fair value	—
Contingent consideration as of September 30, 2021	$	5,230

NOTE 19. HEDGING INSTRUMENTS

Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”), how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows.

We are exposed to certain risks related to our ongoing business operations. The primary risk that we currently manage by using hedging instruments is foreign currency exchange risk. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility.

Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other

foreign currency exchange contracts, cross currency swaps or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries.

The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, and Australian dollar. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.

We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, changes in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See “Note 14. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on our unaudited condensed consolidated statements of income for the three and nine months ended September 30, 2021 and 2020.

We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the unaudited condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged.

Cash Flow Hedges

We have designated our foreign currency exchange contracts as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.

We did not de-designate any instruments from hedge accounting treatment during either the three and nine months ended September 30, 2021 or 2020. At September 30, 2021, the estimated amount of net gains, net of tax, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $2.0 million if exchange rates do not fluctuate from the levels at September 30, 2021.

We target to hedge approximately 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $223.8 million and $202.7 million at September 30, 2021 and December 31, 2020, respectively.

The following tables present the effect of cash flow hedge accounting on our unaudited condensed consolidated statements of income and comprehensive income, and provide information regarding the location and amounts of pretax gains or losses of derivatives:



(in thousands)		Three Months Ended September 30,
		2021		2020

Financial statement line items in which effects of cash flow hedges are recorded	Cost of revenue	$	337,500	$	299,183
Foreign exchange contracts
Amount of (loss) gain reclassified from accumulated other comprehensive income into income		$	(1,583)	$	(591)


(in thousands)		Nine Months Ended September 30,
		2021		2020

Financial statement line items in which effects of cash flow hedges are recorded	Cost of revenue	$	981,259	$	824,179
Foreign exchange contracts
Amount of (loss) gain reclassified from accumulated other comprehensive income into income		$	(6,728)	$	2,562

Net Investment Hedges, Euro-Denominated Notes

In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million in euro-denominated 1.785% Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded gains of $1.6 million and gains of $4.2 million, net of tax, within AOCI as a result of this net investment hedge for the three and nine months ended September 30, 2021, respectively, and losses of $2.8 million and $3.5 million for the three and nine months ended September 30, 2020, respectively. The related cumulative unrealized loss recorded at September 30, 2021, will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 13 to the consolidated financial statements included in our 2020 Annual Report for further information regarding the issuance of these euro-denominated notes.

Net Investment Hedges, Cross Currency Swaps

We have entered into several cross currency swap contracts as a hedge of our net investment in foreign operations to offset foreign currency translation gains and losses on the net investment. These cross currency swaps have maturity dates beginning on June 30, 2023, through June 18, 2025. At maturity of the cross currency swap contracts, we will deliver the notional amount of €90.0 million and will receive approximately $104.5 million from the counterparties on June 30, 2023, and we will deliver the notional amount of €15 million and will receive approximately $17.5 million from the counterparties on June 18, 2025. The change in fair value of the cross currency swap contracts are recorded in AOCI and will be reclassified to earnings when the foreign subsidiaries are sold or substantially liquidated. During the three and nine months ended September 30, 2021, we recorded gains of $2.4 million and gains of $4.6 million, respectively, net of tax, within AOCI as a result of these net investment hedges, and losses of $3.9 million and $1.3 million during the three and nine months ended September 30, 2020, respectively. We will receive quarterly interest payments from the counterparties based on a fixed interest rate until maturity of the cross currency swaps. This interest rate component is excluded from the assessment of hedge effectiveness and, thus is recognized as a reduction to interest expense over the life of the hedge instrument. We recognized approximately $0.7 million and $2.1 million related to the excluded component as a reduction of interest expense for the three and nine months ended September 30, 2021, respectively, and $0.7 million and $2.0 million for the three and nine months ended September 30, 2020, respectively.

Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets

The fair values of hedging instruments and their respective classification on our unaudited condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following derivative instruments, unless otherwise noted:


(in thousands)		Hedging Assets
		September 30, 2021		December 31, 2020

Derivatives and non-derivatives designated as hedging instruments	Balance Sheet Classification
Foreign currency exchange contracts	Other current assets	$	3,996	$	125
Cross currency swaps	Other long-term assets	3,158		—
Foreign currency exchange contracts	Other long-term assets	1,079		—
Total derivative instruments presented as hedge instruments on the balance sheet		8,233		125
Gross amounts subject to master netting arrangements not offset on the balance sheet		(1,630)		(125)
Net amount		$	6,603	$	—


(in thousands)		Hedging Liabilities
		September 30, 2021		December 31, 2020

Derivatives and non-derivatives designated as hedging instruments	Balance Sheet Classification
Foreign currency exchange contracts	Accrued liabilities	$	1,686	$	12,373
Cross currency swaps	Other long-term liabilities	—		2,841
Foreign currency exchange contracts	Other long-term liabilities	12		—
Total derivative instruments presented as cash flow hedges on the balance sheet		1,698		15,214
Non-derivative foreign currency denominated debt designated as net investment hedge on the balance sheet (1)	Long-term debt	103,555		109,125
Total hedging instruments presented on the balance sheet		105,253		124,339
Gross amounts subject to master netting arrangements not offset on the balance sheet		(1,630)		(125)
Net amount		$	103,623	$	124,214

(1) Amounts represent reported carrying amounts of our foreign currency denominated debt. See “Note 18. Fair Value Measurements” for information regarding the fair value of our long-term debt.

Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.